Is GlaxoSmithKline PLC Stock a Good Investment?
GlaxoSmithKline PLC Investment Advice | GSK |
- Examine GlaxoSmithKline PLC's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research GlaxoSmithKline PLC's leadership team and their track record. Good management can help GlaxoSmithKline PLC navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact GlaxoSmithKline PLC's business and its evolving consumer preferences.
- Compare GlaxoSmithKline PLC's performance and market position to its competitors. Analyze how GlaxoSmithKline PLC is positioned in terms of product offerings, innovation, and market share.
- Check if GlaxoSmithKline PLC pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about GlaxoSmithKline PLC's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in GlaxoSmithKline PLC ADR stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GlaxoSmithKline PLC ADR is a good investment.
Sell | Buy |
Strong Buy
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine GlaxoSmithKline PLC Stock
Researching GlaxoSmithKline PLC's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company shares are owned by institutional investors. The book value of GlaxoSmithKline PLC was currently reported as 3.35. The company has Price/Earnings To Growth (PEG) ratio of 0.83. GlaxoSmithKline PLC ADR last dividend was issued on the 21st of February 2025. The entity had 1226:1000 split on the 22nd of July 2022.
To determine if GlaxoSmithKline PLC is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GlaxoSmithKline PLC's research are outlined below:
| GlaxoSmithKline PLC has a strong financial position based on the latest SEC filings | |
| Latest headline from zdnet.com: How to delete your 23andMe data and why you should do it now |
GlaxoSmithKline PLC Quarterly Good Will |
|
GlaxoSmithKline PLC uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GlaxoSmithKline PLC ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GlaxoSmithKline PLC's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 31st of January 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 31st of January 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact GlaxoSmithKline PLC's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises GlaxoSmithKline PLC's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-07-29 | 2020-06-30 | 0.64 | 0.57 | -0.07 | 10 | ||
2016-02-03 | 2015-12-31 | 0.61 | 0.69 | 0.08 | 13 | ||
1995-02-07 | 1994-12-31 | 0.9 | 0.99 | 0.09 | 10 | ||
2025-02-05 | 2024-12-31 | 0.4876 | 0.5792 | 0.0916 | 18 | ||
2023-07-26 | 2023-06-30 | 0.87 | 0.97 | 0.1 | 11 | ||
2004-10-28 | 2004-09-30 | 0.89 | 0.99 | 0.1 | 11 | ||
2024-07-31 | 2024-06-30 | 0.99 | 1.1 | 0.11 | 11 | ||
2023-02-01 | 2022-12-31 | 0.5 | 0.61 | 0.11 | 22 |
GlaxoSmithKline PLC Target Price Consensus
GlaxoSmithKline target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. GlaxoSmithKline PLC's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Buy |
Most GlaxoSmithKline analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand GlaxoSmithKline stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of GlaxoSmithKline PLC ADR, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGlaxoSmithKline PLC Target Price Projection
GlaxoSmithKline PLC's current and average target prices are 38.37 and 45.07, respectively. The current price of GlaxoSmithKline PLC is the price at which GlaxoSmithKline PLC ADR is currently trading. On the other hand, GlaxoSmithKline PLC's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
GlaxoSmithKline PLC Market Quote on 26th of March 2025
Target Price
Analyst Consensus On GlaxoSmithKline PLC Target Price
GlaxoSmithKline PLC Analyst Ratings
GlaxoSmithKline PLC's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about GlaxoSmithKline PLC stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of GlaxoSmithKline PLC's financials, market performance, and future outlook by experienced professionals. GlaxoSmithKline PLC's historical ratings below, therefore, can serve as a valuable tool for investors.Know GlaxoSmithKline PLC's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlaxoSmithKline PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlaxoSmithKline PLC ADR backward and forwards among themselves. GlaxoSmithKline PLC's institutional investor refers to the entity that pools money to purchase GlaxoSmithKline PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 5.7 M | Hotchkis & Wiley Capital Management Llc | 2024-12-31 | 4.6 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2024-12-31 | 4.2 M | Equity Investment Corp | 2024-12-31 | 4 M | Eversept Partners, Llc | 2024-12-31 | 3.7 M | Renaissance Technologies Corp | 2024-12-31 | 2.8 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 2.6 M | Camber Capital Management Llc | 2024-12-31 | 2.5 M | Armistice Capital, Llc | 2024-12-31 | 2.4 M | Dodge & Cox | 2024-12-31 | 68.4 M | Fmr Inc | 2024-12-31 | 52.8 M |
GlaxoSmithKline PLC's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 79.61 B.Market Cap |
|
GlaxoSmithKline PLC's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.07 | 0.07 | |
| Return On Capital Employed | 0.11 | 0.10 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.19 | 0.18 |
Determining GlaxoSmithKline PLC's profitability involves analyzing its financial statements and using various financial metrics to determine if GlaxoSmithKline PLC is a good buy. For example, gross profit margin measures GlaxoSmithKline PLC's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GlaxoSmithKline PLC's profitability and make more informed investment decisions.
Evaluate GlaxoSmithKline PLC's management efficiency
GlaxoSmithKline PLC ADR has Return on Asset of 0.0653 % which means that on every $100 spent on assets, it made $0.0653 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.228 %, implying that it generated $0.228 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.07. The value of Return On Capital Employed is expected to slide to 0.10. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.5 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.21 | 3.37 | |
| Tangible Book Value Per Share | (2.31) | (2.19) | |
| Enterprise Value Over EBITDA | 10.23 | 17.07 | |
| Price Book Value Ratio | 4.02 | 3.81 | |
| Enterprise Value Multiple | 10.23 | 17.07 | |
| Price Fair Value | 4.02 | 3.81 | |
| Enterprise Value | 61.1 B | 44.8 B |
Leadership at GlaxoSmithKline PLC emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Basic technical analysis of GlaxoSmithKline Stock
As of the 26th of March, GlaxoSmithKline PLC retains the risk adjusted performance of 0.1106, and Market Risk Adjusted Performance of 0.5789. GlaxoSmithKline PLC technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.GlaxoSmithKline PLC's Outstanding Corporate Bonds
GlaxoSmithKline PLC issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlaxoSmithKline PLC ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlaxoSmithKline bonds can be classified according to their maturity, which is the date when GlaxoSmithKline PLC ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| GLAXOSMITHKLINE CAPITAL PLC Corp BondUS377373AH85 | View | |
| US377320AA45 Corp BondUS377320AA45 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AM97 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AN70 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AB33 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AJ68 | View | |
| GLAXOSMITHKLINE CAP INC Corp BondUS377372AE71 | View |
Understand GlaxoSmithKline PLC's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing GlaxoSmithKline PLC's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1106 | |||
| Market Risk Adjusted Performance | 0.5789 | |||
| Mean Deviation | 1.2 | |||
| Semi Deviation | 1.24 | |||
| Downside Deviation | 1.39 | |||
| Coefficient Of Variation | 799.23 | |||
| Standard Deviation | 1.69 | |||
| Variance | 2.86 | |||
| Information Ratio | 0.1176 | |||
| Jensen Alpha | 0.2008 | |||
| Total Risk Alpha | 0.1961 | |||
| Sortino Ratio | 0.1434 | |||
| Treynor Ratio | 0.5689 | |||
| Maximum Drawdown | 11.7 | |||
| Value At Risk | (2.03) | |||
| Potential Upside | 2.24 | |||
| Downside Variance | 1.93 | |||
| Semi Variance | 1.53 | |||
| Expected Short fall | (1.33) | |||
| Skewness | 1.53 | |||
| Kurtosis | 6.73 |
| Risk Adjusted Performance | 0.1106 | |||
| Market Risk Adjusted Performance | 0.5789 | |||
| Mean Deviation | 1.2 | |||
| Semi Deviation | 1.24 | |||
| Downside Deviation | 1.39 | |||
| Coefficient Of Variation | 799.23 | |||
| Standard Deviation | 1.69 | |||
| Variance | 2.86 | |||
| Information Ratio | 0.1176 | |||
| Jensen Alpha | 0.2008 | |||
| Total Risk Alpha | 0.1961 | |||
| Sortino Ratio | 0.1434 | |||
| Treynor Ratio | 0.5689 | |||
| Maximum Drawdown | 11.7 | |||
| Value At Risk | (2.03) | |||
| Potential Upside | 2.24 | |||
| Downside Variance | 1.93 | |||
| Semi Variance | 1.53 | |||
| Expected Short fall | (1.33) | |||
| Skewness | 1.53 | |||
| Kurtosis | 6.73 |
Consider GlaxoSmithKline PLC's intraday indicators
GlaxoSmithKline PLC intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GlaxoSmithKline PLC stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 38.37 | |||
| Day Typical Price | 38.37 | |||
| Price Action Indicator | (0.11) | |||
| Period Momentum Indicator | (0.21) | |||
| Relative Strength Index | 60.28 |
GlaxoSmithKline PLC Corporate Filings
6K | 25th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
FWP | 7th of March 2025 A written communication used by offering participants to offer securities to the public or to solicit securities transactions. | ViewVerify |
GlaxoSmithKline Stock media impact
Far too much social signal, news, headlines, and media speculation about GlaxoSmithKline PLC that are available to investors today. That information is available publicly through GlaxoSmithKline media outlets and privately through word of mouth or via GlaxoSmithKline internal channels. However, regardless of the origin, that massive amount of GlaxoSmithKline data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of GlaxoSmithKline PLC news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GlaxoSmithKline PLC relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GlaxoSmithKline PLC's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GlaxoSmithKline PLC alpha.
GlaxoSmithKline PLC Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards GlaxoSmithKline PLC can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
GlaxoSmithKline PLC ADR Historical Investor Sentiment
Investor biases related to GlaxoSmithKline PLC's public news can be used to forecast risks associated with an investment in GlaxoSmithKline. The trend in average sentiment can be used to explain how an investor holding GlaxoSmithKline can time the market purely based on public headlines and social activities around GlaxoSmithKline PLC ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
GlaxoSmithKline PLC's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for GlaxoSmithKline PLC and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average GlaxoSmithKline PLC news discussions. The higher the estimate score, the more favorable the investor's outlook on GlaxoSmithKline PLC.
GlaxoSmithKline PLC Maximum Pain Price Across May 16th 2025 Option Contracts
GlaxoSmithKline PLC's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of GlaxoSmithKline PLC close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of GlaxoSmithKline PLC's options.
GlaxoSmithKline PLC Corporate Directors
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile | |
| Charles Bancroft | Non-Executive Independent Director | Profile | |
| Vivienne Cox | Independent Non-Executive Director and Workforce Engagement Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.173 | Dividend Share 0.61 | Earnings Share 1.61 | Revenue Per Share | Quarterly Revenue Growth 0.008 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between GlaxoSmithKline PLC's value and its price, as these two are different measures arrived at by various means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.